Advertisement

Flavonoids — Lipoxygenases — Platelet Aggregation

  • R. J. Gryglewski
  • J. Robak
  • J. Swięs
Part of the NATO ASI Series book series (NSSA, volume 95)

Abstract

Flavonoids including flavonols (e.g.quercetin and rutin)are widespread in the plant kingdom and they are concentrated by bees in honey and propolis. Flavonoids interact with many macromolecules in animal cells, change the activity of mammalian enzymes and influence permeability of cell membranes. Controlled trials on the therapeutical efficacy of flavonoids were relatively few, although flavonoids were consistently claimed to show anti-bleeding, anti-thrombotic, anti-inflammatory, anti-allergic, analgesic, cytoprotective, oestrogenic, virusostatic and many other pharmacological actions (Haysteen,1983). In clinical practice, in addition to bioflavonoids, a number of semisynthetic flavonoids has been used.

Keywords

Arachidonic Acid Platelet Aggregation Platelet Rich Plasma Oxygenase Activity Free Radical Scavenge Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baumann, J., and Bruchhausen, F., 1979, (+)-cyanidol-3 as inhibitor of prostaglandin synthetase.Studies on renal medulla and liver of the rat in vitro and in vivo. Naunyn-Schmiedeberg’s Arch. Pharmacol., 306: 85.Google Scholar
  2. Baumann, J., Bruchhausen, F., and Wurm, G., 1979, A structure-activity study on the influence of phenolic compounds and bio-flavonoids on rat renal prostaglandin synthetase, Naunyn-Schmiedeberg’s Arch. Pharmacol., 307: 73.Google Scholar
  3. Baumann, J., Bruchhausen, F., and Wurm, G., 1980 a, Fla-vonoids and related compounds as inhibitors of arachidonic acid peroxidation, Prostaglandins, 20: 627.Google Scholar
  4. Baumann, J., Wurm, G., and Bruchhausen, F., 1980 b, Hemmurg der Prostaglandin-Synthetase durch Flavonoide und Phenolderiviate im Vergleich mit deren 02- Radikalfängereigenschaften, Arch.Pharmazie, 313: 330.Google Scholar
  5. Beretz, A., Cazenave, J. P., and Anton, R., 1982 a, Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure - activity relationship, Agents and Actions, 12: 382.Google Scholar
  6. Beretz, A., Stierle, A., Anton, R., and Cazenave, J. P., 1982 b, Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin, Biochem. Pharmacol., 31: 3597.Google Scholar
  7. Cavallini, L., Bindoli, A., and Siliprandi, N., 1978, Comparative evaluation of antiperoxidative action of silymarin and other flavonoids, Pharmacol. Res. Commun., 10: 133.Google Scholar
  8. Dirks, R. C., Faiman, M. D., and Huyser, E. S., 1982, The role of lipid, free radical initiator and oxygen on the kinetics of lipid peroxidation, Toxicol. appl. Pharmacol., 63: 21.Google Scholar
  9. Duniec, Z., Robak, J., and Gryglewski, R. J., 1983, Antioxidant properties of some chemicals vs their influence on cyclooxygenase and lipoxidase activities, Biochem. Pharmacol., 32: 2283.Google Scholar
  10. Dutilh, C. E., Haddeman, E., and ten Hoor, F., 1980, Role of the arachidonate lipoxygenase pathway in blood platelets aggregation, in: Advances in Prostaglandin and Thromboxane Research, B. Samuelsson, P. W. Ramwell, and R. Paoletti, Raven Press, New York. p 101.Google Scholar
  11. Egan, R. W., Gale, P. H., Beveridge, G. C., Harnett, J., and Kuehl, F. A., 1980, Direct and indirect involvement of radical scavengers during prostaglandin biosynthesis, in: Advances in Prostaglandin and Thromboxane Research, B.Samuelsson, P. W. Ramwell, and R. Paoletti, Raven Press, New York, p 153.Google Scholar
  12. Fiebrich, F., Koch, H., 1979, Silymarin an inhibitor of lipoxygenase, Experientia, 35: 1548.Google Scholar
  13. Griffiths, R. J., Lofts, F. J., and Moore, P. K., 1983, The effects of drugs on the synthesis of 6-oxoprostaglandin E1, Brit. J. Pharmac., 78: 51P.Google Scholar
  14. Gryglewski, R. J., Bunting, S., Moncada, S., Flower, R. J., and Vane, J. R., Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides, Prostaglandins, 12: 685. 1976.PubMedCrossRefGoogle Scholar
  15. Gryglewski, J. R., Korbut, R., Ocetkiewicz, A., and Stachura 3. 1978, In vivo method for quantitation of anti-platelet potency of drugs, Naunyn-Schmie-deberq's Arch.Pharmacol, 302: 25.CrossRefGoogle Scholar
  16. HammarstrÖm, S., and Diczfalusy, U., 1980, Biosynthesis of thromboxanes, in: Advances in Prostaglandins and Thromboxane Research, B.Samuelsson, P. W. Ramwell, and R. Paoletti, Raven Press, New York, p267.Google Scholar
  17. Haysteen, B., 1983, Flavonoids, a class of natural products of high pharmacological potency, Biochem. Pharmacol., 32: 1141.Google Scholar
  18. Hope, W.,We Iton, A. F., Fiedler-Nagy, C., Batula-Bernardo, C., and Coffey, J.W., 1983, In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase activity by quercetin, Biochem. Pharmacol., 32: 367.Google Scholar
  19. Kuehl, F. A., Humes, J. L., Egan, R. W., Ham, E. A., Beveridge, G. C., Van Arman, C. G., 1977, Role of prostaglandin endoperoxide PGG2 in inflammatory process, Nature, 265: 170.PubMedCrossRefGoogle Scholar
  20. Kulmacz, R. J., an Lands, E. M., Characteristics of prostaglandin H synthese, in: Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Samuelsson, R. Paoletti, and P. W. Ramwell, Raven Press, New York, 1983, p 93.Google Scholar
  21. Landolfi, R., Mower, R. L., and Steiner, M., 1984, Biochem. Pharmacol., 33: 1525.PubMedCrossRefGoogle Scholar
  22. Lee, T. P., Mateliano, M. L., and Middleton, E., Effect of quercetin on human polymorphonuclear leukocyte lysosomal enzyme release and phospholipid metabolism, 1982, Life Sci, 31: 2765.PubMedCrossRefGoogle Scholar
  23. Maclouf, J., Fruteau de aacclos, B., and Borgeat, P., 1983, Effects of 12-hydroxy and 12-hydroperoxy 5,8,10,14-eicosatetraenoic acids on the synthesis of 5-hydroxy-6,8,11,14-eicosotetraenoic acid and leukotriene B4 in human blood leukocytes, in: Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Samuelsson, R. Paoletti, and P. W. Ramwell, Raven Press, New York, p 159.Google Scholar
  24. Marcus, A. J., Brockman, J., Safier, L. B., Ullman, H. L., and Islam, N., 1982, Formation of leukotrienes and other hydroxy acids during plateletneutrophil interactions in vitro, Biochem. Biophys. Res. Commun., 109: 130.Google Scholar
  25. Moore, P. K., Griffiths, R. J., and Lofts, F. J., 1983, The effects of some flavone drugs on the conversion of prostacyclin to 6-oxo-prostaglandin E1, Biochem. Pharmacol., 32: 2813.Google Scholar
  26. Mower, R. L., Landolfi, R., and Steiner, M., 1984, Inhibition in vitro of platelet aggregation and arachidonic acid metabolism by flavone, Biochem. Pharmacol., 33: 257.Google Scholar
  27. Pollock and Heath, H., 1975, Studies on the effects of ββ -iminadiproprionitrile and b- (fβ-hydroxyethyl)-rutoside on ADP-activated aggregation of rat platelets in relation to the development of diabetic microangiopathy, Biochem.Pharmacol., 24: 397.CrossRefGoogle Scholar
  28. Robak, J., and Duniec, Z., 1980, The influence of chlorpromazine on lipoxidases, Biophys. Biochim. Acta, 620: 59.Google Scholar
  29. Robak, J., and Duniec, Z., 1982, The influence of some 3-amino-2-pyrazoline derivatives on cyclooxygenase and lipoxidase activities, Biochem. Phar-macol., 31: 1955.Google Scholar
  30. Robak, J.. Duniec, Z., Grodzinska, L., and Zachwieja, Z., 1981, The influence of some cinnamic acid derivatives on cyclooxygenase and lipoxidase activities, Pol. J. Pharmacol. Pharm., 33: 521.Google Scholar
  31. Sams, A. R., Sprecher, H., Sankarppa, S. K., and Needleman, P., 1982, Selective inhibitors of platelet arachidonic acid metabolism: aggregation independent of lipoxygenase, in: Leukotrienes and other Lipoxygenase Products, B. Samuelsson, and R. Paoletti, Raven Press, New York, p 19.Google Scholar
  32. Sekiya, K., and Okuda, H., 1982, Selective inhibition of platelet lipoxygenase by baicalein, Biochem. Biophys. Res. Commun., 105: 1090.Google Scholar
  33. Sekiya, K., Okuda, H., and Arichi, S., 1982, Selective inhibition of platelet lipoxygenase by exculetin, Biophys. Biochim. Acta, 713: 68.Google Scholar
  34. Sun, F. F., McGuire, J. C., Wallach, D. P., and Brown, V. R., 1980, Study on the property and inhibition of human platelet arachidonic acid 12-lipo-xygenase, in: Advances in Prostaglandin and Thromboxane Research, B. Samuelsson, P. W. Ram-well, and R. Paoletti, Raven Press, New York, p 111.Google Scholar
  35. Swies, J., Dabrowski, L., Duniec, Z., Michalska, Z., Robak, J., and Gryglewski, R. J., 1984, Antiaggregatory effects of flavonoids in vivo and their influence on lipoxygenase and cyclooxygenase in vitro, Pol. J. Pharmacol. Pharm.,in press.Google Scholar
  36. Tauber, A. J., Fay, J. R., and Marletta, M. A., 1984, Flavonoid inhibition of the human neutrophil NADPH-oxidase, Biochem. Pharmacol., 33: 1367.Google Scholar
  37. Vargaftig, B. B., Chignard, H., Lefort, J.. Wal, F., le Couedic, J. P., and Benveniste, J., 1982. Platelet aggregation independent of prostaglandin formation: Pharmacological properties and the hypothetical role of platelet activating factor, in: Cardiovascular Pharmacology of the Prostaglandins, A. G. Herman, P. M. Vanhoutte, H. Denolin, and A. Goossens, Raven Press, New York, p 161.Google Scholar
  38. Vargas, J. R., Radomski, M., and Moncada, S., 1982, The use of prostacyclin in the separation from plasma and washing of human platelets, Prostaglandins, 23: 929.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • R. J. Gryglewski
    • 1
  • J. Robak
    • 1
  • J. Swięs
    • 1
  1. 1.Department of PharmacologyN.Copernicus Academy of Medicine in CracowCracowPoland

Personalised recommendations